Form 4: Avidity Biosciences Chief Medical Officer Acquires Shares and Options

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.

Summary

• Steven George Hughes, Chief Medical Officer of Avidity Biosciences, acquired 25,000 restricted stock units (RSUs) and 50,000 stock options on January 6, 2025.
• The RSUs vest in four equal installments on the first four anniversaries of January 6, 2025, contingent on continuous service.
• The stock options vest in 48 equal monthly installments from the grant date, fully vesting on January 6, 2029.
• The exercise price of the stock options is $31.42.
• Following these transactions, Mr. Hughes beneficially owns 86,375 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a key executive, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of shares and options by the Chief Medical Officer demonstrates confidence in the company's future.
• The vesting schedules for both RSUs and options align with long-term value creation and retention.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment from the Chief Medical Officer to the company's success.

Industry Context

This type of equity compensation is common in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants to executives are a standard practice in the biotech industry, often including a mix of stock options and restricted stock units.
• Vesting schedules are typically structured to align with long-term performance and retention, with monthly or annual vesting periods being common.
• The specific terms of the grants, such as the exercise price of $31.42, would need to be compared to similar grants at peer companies to assess their competitiveness.

Stakeholder Impact

• The equity grants align the Chief Medical Officer's interests with those of shareholders, potentially leading to increased value creation.
• The vesting schedule encourages long-term commitment from the executive, which can be beneficial for the company's stability and growth.

Key Dates

Keywords

Avidity Biosciences, Steven George Hughes, Chief Medical Officer, stock options, restricted stock units, RSUs, insider trading, equity compensation, vesting